Cancer drug funding decisions in Scotland: impact of new end-of-life, orphan and ultra-orphan processes

BACKGROUND: The Scottish Medicines Consortium evaluates new drugs for use in the National Health Service in Scotland. Reforms in 2014 to their evaluation process aimed to increase patient access to new drugs for end-of-life or rare conditions; the changes include additional steps in the process to g...

Descripción completa

Detalles Bibliográficos
Autores principales: Morrell, Liz, Wordsworth, Sarah, Fu, Howell, Rees, Sian, Barker, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5577765/
https://www.ncbi.nlm.nih.gov/pubmed/28854927
http://dx.doi.org/10.1186/s12913-017-2561-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5577765/
https://www.ncbi.nlm.nih.gov/pubmed/28854927
http://dx.doi.org/10.1186/s12913-017-2561-0

Ejemplares similares